Yarrow Bioscience
YARW
44 hedge funds and large institutions have $13.4M invested in Yarrow Bioscience in 2025 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 7 closing their positions.
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
16% more capital invested
Capital invested by funds: $11.5M → $13.4M (+$1.88M)
16% more funds holding
Funds holding: 38 → 44 (+6)
6.17% more ownership
Funds ownership: 47.09% → 53.26% (+6.2%)
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$1.78M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$742K |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$390K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$377K |
| 5 |
Jane Street
New York
|
+$162K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$2.37M |
| 2 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$344K |
| 3 |
EAM
Exome Asset Management
New York
|
-$330K |
| 4 |
Renaissance Technologies
New York
|
-$136K |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$111K |
YARW Hedge Fund Activity: Q2 2025 in Review
44 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience (YARW) for Q2 2025, worth a combined $13.4M — up 16% from $11.5M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new YARW positions and 7 closed out — a net gain of 6 holders — while 8 added to existing stakes and 12 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $1.78M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $2.37M sold.
- 44 institutional investors held Yarrow Bioscience (YARW) as of Q2 2025, up from 38 in Q1 2025.
- Funds reported $13.4M of Yarrow Bioscience stock for Q2 2025, up 16% quarter-over-quarter.
- 13 funds opened new Yarrow Bioscience positions in Q2 2025 and 7 closed out, a net change of +6 holders.
- The largest Yarrow Bioscience buyer in Q2 2025 was Cormorant Asset Management, an estimated $1.78M added.
- The largest Yarrow Bioscience seller in Q2 2025 was Eventide Asset Management, an estimated $2.37M sold.
Based on aggregated 13F filings for Q2 2025.